Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib Long-term Extension in Psoriatic Arthritis
NCT03320876Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Jul 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of filgotinib in psoriatic arthritis (PsA), sponsored by Galapagos NV. Started Jul 2017; status: terminated.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03320876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320876.